#USA #Los Angeles #Schall Law Firm #CAPR #Capricor

Investors Urged to Join Class Action Against Capricor Therapeutics

The Schall Law Firm has called upon investors who suffered losses to join a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). The case centers around allegations of securities fraud, specifically violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, alongside Rule 10b-5, as outlined by the U.S. Securities and Exchange Commission (SEC).

Key Information for Investors

Investors who purchased Capricor's securities from October 9, 2024, to July 10, 2025, known as the "Class Period," are urged to contact the firm before the deadline of September 15, 2025. It is vital for affected shareholders to take this opportunity to potentially recover their losses.

The Allegations

The complaint alleges that throughout the Class Period, Capricor made false and misleading statements concerning the company’s progress toward FDA approval for its drug candidate, deramiocel. This included positive reports such as a mid-cycle review with no major deficiencies and plans for an advisory committee meeting. However, the reality is said to have been masked by adverse data from the Phase 2 HOPE-2 trial, which was not disclosed to investors.

As the truth emerged, investors faced substantial losses. The class action seeks to hold Capricor accountable for the alleged deceptions that led to this situation.

Participation in the Lawsuit

Investors interested in participating are encouraged to reach out to Brian Schall at the Schall Law Firm. The firm's office, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, can be contacted at 310-301-3335. Alternatively, interested individuals can visit the firm's website at www.schallfirm.com or email inquiries to the firm.

It is important to note that, as of now, the class has not yet been certified. Until this process is finalized, individuals who opt not to join will not have legal representation. If you choose to remain inactive, you will still have the status of an absent class member.

The Role of the Schall Law Firm

The Schall Law Firm has made its name as a significant advocate for shareholders across the globe, specializing in securities class action lawsuits. They aim not only to recover losses for investors but also to uphold shareholder rights and transparency within financial markets.

Given the serious implications of the allegations against Capricor, it’s crucial for investors to understand their legal options. The therapeutic landscape, especially in biotech, can be fraught with uncertainty, making investor protection and legal recourse even more critical. Investors are reminded that any action taken now is pivotal to potentially recouping their financial setbacks.

In conclusion, the invitation from the Schall Law Firm serves as an essential wake-up call for those impacted by the developments at Capricor Therapeutics. With the chance to participate in a class action lawsuit, investors are urged to take a proactive stance.

Investors must act swiftly, as the window for joining this important legal action is limited. By standing together, shareholders can work to assert their rights and seek justice in the face of alleged corporate misconduct.